JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 2 No. 10, October 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contributions
 This Article
 •Abstract
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

An Overview of the Efficacy and Safety of Fenfluramine and Mazindol in the Treatment of Obesity

Keith A. Stahl, MD; Thomas F. Imperiale, MD

Arch Fam Med. 1993;2(10):1033-1038.


References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.


1. Gray DS. Diagnosis and prevalence of obesity. Med Clin North Am. 1989;73:1-13. PUBMED
2. NIH Conference. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956-961. FREE FULL TEXT
3. Hirsch J. Barriers to treating obesity. Ann Intern Med. 1991;115:656. FREE FULL TEXT
4. Elliot DL, Goldbert L. Barriers to treating obesity. Ann Intern Med. 1991;115:656-657. FREE FULL TEXT
5. Bray GA. Barriers to the treatment of obesity. Ann Intern Med. 1991;115:152-153. FREE FULL TEXT
6. Der Simonian R, Laird N. Combining evidence in clinical trials. Controlled Clin Trials. 1986;7:177-188. PUBMED
7. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press; 1985.
8. Maclay W, Wallace M. A multi-centre general practice trial of mazindol in the treatment of obesity. Practitioner. 1977;218:431-434. PUBMED
9. Brun L, Bielmann P, Gagne C, Moorjani S, Nadeau A, Lupien PJ. Effects of fenfluramine in hypertriglyceridemic obese subjects. Int J Obes. 1988;12:423-431. PUBMED
10. Goldrick R, Nestel P, Havenstein N. Comparison of a new anorectic agent AN448 with fenfluramine in the treatment of refractory obesity. Med J Aust. 1974;1:882-885. PUBMED
11. Sedgwick J. Mazindol in the treatment of obesity. Practitioner. 1975;214:418-420. PUBMED
12. Tisdale S, Ervin D. Anorectic effectiveness of differing dosage forms of fenfluramine. Curr Ther Res. 1976;19:589-594. PUBMED
13. Smith R, Innes J, Munro JF. Double-blind evaluation of mazindol in refractory obesity. BMJ. 1975;3:284. FREE FULL TEXT
14. Wallace A. AN448 Sandoz (mazindol) in the treatment of obesity. Med J Aust. 1976;1:343-345. PUBMED
15. Weintraub M, Sriwatanakul K, Sundaresan P, Weis OF, Dorn M. Extendedrelease fenfluramine: patient acceptance and efficacy of evening dosing. Clin Pharmacol Ther. 1983;33:621-627. PUBMED
16. Smith D. A new anorexiant: clinical evaluation. Rocky Mountain Med J. 1974;71:41-44. PUBMED
17. Walker B, Ballard I, Gold J. A multicentre study comparing mazindol and placebo in obese patients. J Int Med Res. 1977;5:85-90. PUBMED
18. Steel J, Munro J, Duncan L. A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner. 1973;211:232-236. PUBMED
19. Thorpe P, Isaac P, Rodgers J. A controlled trial of mazindol (sanorex, teronac) in the management of the obese rheumatic patients. Curr Ther Res. 1975;17:149-155. PUBMED
20. Elmaleh M, Miller J. Controlled clinical evaluation of a new anorectic agent in obese adults. Pa Med. 1974;77:46-50. PUBMED
21. Munro J, Seaton D, Duncan L. Treatment of refractory obesity with fenfluramine. BMJ. 1966;2:624-625. FREE FULL TEXT
22. Heber A. Double-blind trial of mazindol in overweight patients. Med J Aust. 1975;2:566-567. PUBMED
23. Woodhouse S, Nye ER, Anderson K, Rawlings J. A double-blind controlled trial of a new anorectic agent AN448. NZ Med J. 1975;81:546-549. PUBMED
24. Vernace B. Controlled comparative investigation of mazindol, D-amphetamine, and placebo. Obes/Bariatr Med. 1974;3:124-129.
25. Schwartz L. A non-amphetamine anorectic agent: preclinical background and a double-blind clinical trial. J Int Med Res. 1975;3:328-332.
26. Stunkard A, Rickels K, Hesbacker P. Fenfluramine in the treatment of obesity. Lancet. 1973;1:503-505. PUBMED
27. Persson I, Anderson U, Deckert T. Treatment of obesity with fenfluramine. Eur J Clin Pharmacol. 1973;6:93-97. PUBMED
28. Galloway D, Logie A, Petrie J. Prolonged-action fenfluramine in non-diabetic patients with refractory obesity. Postgrad Med J. 1975;51(suppl):155-157. PUBMED
29. Sainani G, Fulambarkar A, Khurana B. A double-blind clinical trial of fenfluramine in the treatment of obesity. Br J Clin Pract. 1973;27:136-138. PUBMED
30. Follows O. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Br J Clin Pract. 1971;25:236-238. PUBMED
31. Maneksha S. Prolonged-action fenfluramine capsules versus fenfluramine tablets in general practice. Br J Clin Pract. 1975;29:12-13. PUBMED
32. Owen J. Prolonged action fenfluramine in general practice. Br J Clin Pract 1975;29:13-14. PUBMED
33. Traherne J. A clinical trial of fenfluramine. Practitioner. 1965;195:677-680. PUBMED
34. Lele R, Joshi V, Nathwani A. A double-blind clinical trial of fenfluramine. Br J Clin Pract. 1972;26:79-82. PUBMED
35. Haugen H. Double blind cross-over study of a new appetite suppressant AN448. Eur J Clin Pharmacol. 1975;8:71-74. PUBMED
36. Miach P, Thomson W, Doyle AE, Louis WJ. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients. Med J Aust. 1976;2:378-380. PUBMED
37. Hossain M, Campbell D. Fenfluramine and methylcellulose in the treatment of obesity: the relationship between plasma drug concentrations and therapeutic efficacy. Postgrad Med J. 1975;51(suppl):178-182. FREE FULL TEXT
38. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143-1148. FREE FULL TEXT
39. Kornhaber A. Obesity-depression: clinical evaluation with a new anorexigenic agent. Psychosomatics. 1973;14:162-167. FREE FULL TEXT
40. Lawson A, Roscoe P, Strong J, Gibson A, Peattie P. Comparison of fenfluramine and metformin in treatment of obesity. Lancet. 1970;2:437-441. PUBMED
41. Cameron DC, Kennedy WP, Samuel PD, Crompton GK. Fenfluramine in corticosteroid-induced obesity. Curr Med Res Opin. 1972;1:153-158. PUBMED
42. Douglas JG, Preston PG, Haslett C, et al. Long term efficacy of fenfluramine in treatment of obesity. Lancet. 1983;1:384-386. PUBMED
43. Tomlinson S, Lines J, Greenfield MAM. The effect of fenfluramine on obesity and plasma lipids of patients with renal allografts. Postgrad Med J. 1975;51(suppl):166-170. FREE FULL TEXT
44. Innes JA, Campbell IW, Millar J, Munro JF. A comparison of the efficacy and acceptability of fenfluramine tablets (BP) and prolonged action capsules. Post-grad Med J.J. 1975;51(suppl):160-162.
45. Adadevoh B. Therapeutic effect of fenfluramine in obese Nigerians: clinical, metabolic, and hypotensive properties. Postgrad Med J. 1975;51(suppl):158. Abstract. PUBMED
46. Balasse EO, Couturier E, Kornitzer M, Degre S. Influence of a long acting preparation of fenfluramine on body weight, body composition and skinfold thickness in obese subjects. Postgrad Med J. 1975;51(suppl):157. Abstract. PUBMED
47. Gaind R. Fenfluramine (Ponderax) in the treatment of obese psychiatric outpatients. Br J Psychiatry. 1969;115:963-964. FREE FULL TEXT
48. Rosenthal R. The 'file drawer problem' tolerance for null results. Psychol Bull. 1979;86:638-641.
49. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. BMJ. 1981;283:881-883. FREE FULL TEXT
50. Pouwels HM, Smeets JL, Cheriex EC, Wouters EF. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990;3:606-607. ABSTRACT
51. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ. 1986;292:239-240. FREE FULL TEXT